Literature DB >> 17624472

Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells.

Yuning Sun1, Daochun Sun, Fang Li, Linlin Tian, Chunrong Li, Lu Li, Ruxian Lin, Shengqi Wang.   

Abstract

Sirt1, a conserved nicotinamide adenine dinucleotide (NAD(+))-dependent deacetylase, has been implicated in modulating transcriptional silencing and cell survival, and seems to play a key role in carcinogenesis through deacetylation of important regulatory proteins. This makes it a potential target in cancer therapy. The purpose of this study was to determine whether inhibition of Sirt1 by using antisense oligonucleotides (ASODN) induces apoptosis and enhances radiation sensitization in A549 lung cancer cells. Initially, transient transfection of A549 lung cancer cells with ASODN against Sirt1 specifically reduced Sirt1 expression in a dose-dependent and sequence-specific manner, at both mRNA and proteins levels. The inhibition of Sirt1 obviously decreased A549 cells survival, induced G1 arrest as well as apoptosis. Furthermore, the inhibition of Sirt1 by ASODN greatly increased radiation-induced antiproliferation effects involving in increasing acetylation of tumour suppressor p53 and Bax expression in A549 lung cancer cells. In summary, our results indicate that downregulation of Sirt1 by ASODN decreases survival and increases radiation-induced antiproliferation effects of human lung cancer cells and suggest that inhibition of Sirt1 by ASODN may be a potential gene therapy approach to the treatment of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17624472     DOI: 10.1016/j.lungcan.2007.05.013

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  24 in total

Review 1.  Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer.

Authors:  Brittney Jung-Hynes; Russel J Reiter; Nihal Ahmad
Journal:  J Pineal Res       Date:  2010-01       Impact factor: 13.007

2.  SIRT1 inactivation evokes antitumor activities in NSCLC through the tumor suppressor p27.

Authors:  Lijia Zhu; Christine Y Chiao; Katelyn G Enzer; Alexander J Stankiewicz; Douglas V Faller; Yan Dai
Journal:  Mol Cancer Res       Date:  2014-08-20       Impact factor: 5.852

3.  K-Ras promotes the non-small lung cancer cells survival by cooperating with sirtuin 1 and p27 under ROS stimulation.

Authors:  Dezhi Cheng; Liang Zhao; Yunsheng Xu; Rongying Ou; Gang Li; Han Yang; Wenfeng Li
Journal:  Tumour Biol       Date:  2015-04-19

Review 4.  SIRT3 and cancer: tumor promoter or suppressor?

Authors:  Turki Y Alhazzazi; Pachiyappan Kamarajan; Eric Verdin; Yvonne L Kapila
Journal:  Biochim Biophys Acta       Date:  2011-05-07

5.  Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers.

Authors:  Rodney E Shackelford; Marilyn M Bui; Domenico Coppola; Ardeshir Hakam
Journal:  Int J Clin Exp Pathol       Date:  2010-06-12

Review 6.  Current concepts on the role of inflammation in COPD and lung cancer.

Authors:  Hongwei Yao; Irfan Rahman
Journal:  Curr Opin Pharmacol       Date:  2009-07-15       Impact factor: 5.547

7.  Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients.

Authors:  Ruo-Chia Tseng; Chin-Chu Lee; Han-Shui Hsu; Ching Tzao; Yi-Ching Wang
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

8.  SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer.

Authors:  Weidong Lu; Yun Zuo; Yufang Feng; Min Zhang
Journal:  Tumour Biol       Date:  2014-07-29

Review 9.  Janus-faced role of SIRT1 in tumorigenesis.

Authors:  Na-Young Song; Young-Joon Surh
Journal:  Ann N Y Acad Sci       Date:  2012-10       Impact factor: 5.691

10.  SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas.

Authors:  Kyu Yun Jang; Sang Jae Noh; Nadja Lehwald; Guo-Zhong Tao; David I Bellovin; Ho Sung Park; Woo Sung Moon; Dean W Felsher; Karl G Sylvester
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.